Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | GAK | O14976 | 2/20 | 0.42 |
| ▸ | STK16 | O75716 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287822 | 0.84 | POLB (0.56) | BRD4FLT3HPGD | |
| SCHEMBL4552859 | 0.84 | CDK1 (0.57) | HDAC1AURKAAURKBFLT3HPGD | |
| SCHEMBL4422505 | 0.81 | CFD (0.54) | HDAC1AURKAHPGD | |
| SCHEMBL4427288 | 0.78 | BCHE (0.60) | HDAC1AURKAFLT3HPGD | |
| SCHEMBL5943744 | 0.78 | PARP1 (0.54) | BRD4HDAC1HPGDACLY | |
| SCHEMBL5449209 | 0.77 | MAPT (0.58) | HPGD | |
| SCHEMBL8289907 | 0.76 | HDAC6 (0.55) | HDAC1AURKBFLT3KDRFLT1 | |
| SCHEMBL14875894 | 0.75 | HDAC1 (0.56) | HDAC1HPGDCYP19A1 | |
| SCHEMBL8289903 | 0.74 | HDAC1 (0.51) | HDAC1 | |
| SCHEMBL26043608 | 0.71 | TNIK (0.51) | AAK1HPGDBRAFCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682538-A4 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2009-05-27 | — | — | EP | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| EP-1682538-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*Bio Pte Ltd (SG) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005040161-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040161-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | HDAC1, HDAC11, HDAC2 | BRD4 35/4885HDAC1 1/4885AURKA 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.